Norway Research Council Awards Lytix Biopharma NOK 12 Million
The grant will support extending Lytix Biopharma’s oncolytic platform to deep-seated tumors.
Related stories
InBody Q3 Operating Profit Rises 96.5% Year on Year
M impact | EQUITY | Nov 05, 2026, 06:19 AM UTC
IQM Quantum Computers Reports Q3 Loss of €152.6 Million
M impact | EQUITY | Nov 05, 2026, 06:19 AM UTC
FinecoBank Reports Q3 Net Profit of €188.1 Million
M impact | EQUITY | Nov 05, 2026, 06:18 AM UTC
Deutsche Telekom Q3 Adjusted Net Profit Rises 13% to EUR 3.01 Billion
M impact | EQUITY | Nov 05, 2026, 06:18 AM UTC
Savola Reports Higher Quarterly Food Services Revenue
Savola said quarterly revenue increased in its food services segment; no figures were provided.
M impact | EQUITY | Nov 05, 2026, 06:18 AM UTC
Nekkar Q3 Net Loss Narrows 40% to NOK 3 Million
Nekkar reported a Q3 2026 net loss of NOK 3 million, down 40% year-on-year.
M impact | EQUITY | Nov 05, 2026, 06:18 AM UTC